at YOUR convenience, click here.
We will be pleased to assist you Monday through Thursday from 8 AM to midnight ET, Friday from 8 AM to 6 PM ET, and Saturday from 8 AM to 3 PM ET (with the exception of holidays and certain dates around holidays).
Now, there is a fast and easy way to obtain:
- Samples of FOSAMAX® (alendronate sodium) and FOSAMAX PLUS D
- Access to relevant clinical articles
- The latest product information from Merck
- Educational materials for your patients
- Answers to clinical questions about FOSAMAX, FOSAMAX PLUS D, and osteoporosis
Physicians Contact Merck
If you would prefer to use only the phone, you can speak directly with a Merck representative by calling 1-877-637-2530.
To request to speak with a Merck health care professional about Merck products or services, please call 1-800-672-6372. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.
Consumers Contact Merck
You may suggest that consumers call 1-888-FOSAMAX (1-888-367-2629) between 8 AM and 8 PM ET to receive additional information about FOSAMAX or FOSAMAX PLUS D.
Important Information About FOSAMAX® (alendronate sodium) and FOSAMAX PLUS D
FOSAMAX and FOSAMAX PLUS D are contraindicated in patients with esophageal abnormalities which delay esophageal emptying (eg, stricture or achalasia) and in patients unable to stand or sit upright for at least 30 minutes. Patients at increased risk of aspiration should not receive FOSAMAX oral solution. FOSAMAX and FOSAMAX PLUS D are contraindicated in patients with hypocalcemia (see WARNINGS AND PRECAUTIONS) and in patients with hypersensitivity to any component of these products. Hypersensitivity reactions including urticaria and angioedema have been reported. FOSAMAX and FOSAMAX PLUS D, like other bisphosphonates, may cause local irritation of the upper gastrointestinal mucosa.
In postmarketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates that are approved for the prevention and treatment of osteoporosis. The time to onset of symptoms varied from one day to several months after starting the drug. Discontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping treatment.
Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection, often with delayed healing, has been reported in patients taking bisphosphonates.
Resources for Your Clinical Practice:
Connect to a Merck Representative
You control when and where you get Merck product information and services
Visit MerckServices.com
Your direct line to Merck online resources—24 hours a day, 7 days a week
For Merck product and service information, contact the Merck National Service Center:
1-800-NSC-MERCK
1-800-672-6372